AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
Study NCT02660762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal cytarabine
Description: 50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
Study NCT00900575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Spectroscopy Bench-Top System
Description: This device is a bench-top optical spectrometer
Study NCT00900575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Optical Spectrometer
Description: This device is a portable optical spectrometer
Study NCT00900575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal colposcope
Study NCT04362137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 5 mg tablets
Study NCT04362137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-image placebo
Study NCT03757806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts.
Study NCT03497884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
Study NCT03497884 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
Study NCT00829361 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine
Description: Two way site independent audio/video telemedicine system with DICOM.
Study NCT01763528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention
Description: high protein diet
Study NCT03862703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth intervention, PTSD Help app.
Description: Experimental group will receive the app, PTSD Help.
Study NCT00785538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Study NCT00785538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Study NCT00785538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Study NCT00785538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Study NCT00785538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Study NCT00785538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.
Study NCT02562963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer T cell
Description: The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment.
Study NCT04114357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylated and Butyrylated High Amylose Maize Starch
Description: Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner for 4 weeks
Study NCT06405789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga practice
Description: The researcher has a yoga certificate before the study. The intervention group participated in 15 weeks of yoga/awareness activities led by the researcher. The yoga curriculum for the use of yoga in the classroom had been previously studied with nursing students and permission was obtained for its use in this study \[11\]. The course content consists of 1.5 hours/per week (theoretical: 30 minutes; practical: 60 minutes) Each yoga session includes 5 minutes of breathing (pranayama) and warming up, 40 minutes of postures (asanas), 5 minutes of breathing (pranayama), 5 minutes of corpse pose (shavasana).In addition, to develop mindfulness, after the class, students were offered daily practices that enable a mindfulness-based approach to life events. The students participated in activities such as yoga practice, breathing and relaxation exercises, meditation practices with instructor notes and resources.
Study NCT00514904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Single dose, intramuscular injection
Study NCT00514904 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax
Description: Single dose, subcutaneous injection
Study NCT02284568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02284568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod capsules in 0.5 mg and 0.6 mg strengths
Study NCT02284568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules
Study NCT01037127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Daily oral dosing
Study NCT00006024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study NCT00006024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00734695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin c
Description: Subconjunctival daily or bid
Study NCT00734695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c
Description: topical and systemic
Study NCT00734695 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c
Description: topical systemic
Study NCT03363451 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: This is an observation study, no specific antibiotics will be indicated during treatment
Study NCT03426436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Two consecutive 15-lead ECGs
Description: The 15-lead ECG consists of a traditional 12-lead ECG and an additional three leads on the right side of the body. The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
Study NCT03652636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulfur Hexafluoride Microspheres
Description: 2.5 mL intravenous injection given at the time of ultrasound, with second 2.5 mL intravenous injection given during ultrasound as needed to improve visualization
Study NCT02573766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofeedback Training
Description: Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
Study NCT02573766 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback Training
Description: Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
Study NCT02573766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram
Description: Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
Study NCT02573766 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroencephalogram
Description: Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
Study NCT02573766 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalogram
Description: Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
Study NCT02573766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Scale
Description: Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
Study NCT02573766 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pain Scale
Description: Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
Study NCT02573766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
Study NCT02573766 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Description: Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
Study NCT02573766 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
Study NCT04055376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENUS device (Active Settings)
Description: Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months.
Study NCT04055376 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (Sham Settings)
Description: Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months.
Study NCT03898362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pneumatically powered wheelchair or scooter
Description: a wheelchair or scooter powered by compressed air will be used for 6 months. Compressed air is a novel power source and no batteries are used in these devices.
Study NCT03898362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: battery powered wheelchair or scooter
Description: a wheelchair or scooter powered by a battery will be used for 6 months. These are conventional mobility devices that the participants are using or in the process of obtaining
Study NCT04398654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioMEMSTM HF sensor - pulmonary artery pressure measurement
Description: CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure. Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.
Study NCT02447497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Surgical Skin Preparation - Abdominal Region
Description: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
Study NCT02447497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline - Abdominal Region
Description: 0.9% sodium chloride applied with foam applicator
Study NCT02447497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Surgical Skin Preparation - Inguinal Region
Description: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
Study NCT02447497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline - Inguinal Region
Description: 0.9% sodium chloride applied with foam applicator
Study NCT02872649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Study NCT00991757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carisbamate
Description: Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
Study NCT00515359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Propofol Sedation
Description: Intermittent versus continuous dosage
Study NCT00515359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Propofol Sedation
Description: intermittent vs continuous dosage
Study NCT01342250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional therapy plus low dose hUC-MSCs treatment
Description: patients will receive the conventional therapy plus low dose hUC-MSCs treatment
Study NCT01342250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional therapy plus medium dose hUC-MSCs treatment
Description: patients will receive conventional therapy plus medium dose hUC-MSCs treatment
Study NCT01342250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional therapy plus high dose hUC-MSCs treatment
Description: patients will receive conventional therapy plus high dose hUC-MSCs treatment
Study NCT03147131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
Study NCT03398512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exploratory laparoscopy or laparotomy
Description: Exploratory laparoscopy or laparotomy, for PCI score or radical colorectal resection and cytoreductive surgery
Study NCT03398512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Normal saline 3000ml-4000ml, Raltitrexed 4mg, 43°C, 60min.
Study NCT03398512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: Oxaliplatin: 130mg/m2, day 1. Capecitabine: 1500mg, twice daily for two weeks, and then suspend for one week
Study NCT02520882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-Aca-BBN
Description: 68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
Study NCT02520882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study NCT00189306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
Study NCT02326077 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Monitoring of the mechanism of labor
Study NCT02326077 — intervention group
Intervention type: OTHER
Intervention: Acceptability of ultrasound monitoring of labor
Description: Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor
Study NCT02326077 — intervention group
Intervention type: OTHER
Intervention: Patients' experience regarding intrapartum ultrasound
Description: The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
Study NCT02296580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nativis Voyager RFE Therapy
Description: Nativis Voyager Radiofrequency Energy Therapy
Study NCT02172248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Study NCT02172248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01508026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan 1
Description: Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
Study NCT01508026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan 2
Description: Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
Study NCT01508026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol and Valsartan 3
Description: Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
Study NCT01508026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol 1
Description: Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
Study NCT01508026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol 2
Description: Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
Study NCT01508026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 1
Description: Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
Study NCT01508026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 2
Description: Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
Study NCT01508026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo, oral administration
Study NCT02779309 — intervention group
Intervention type: PROCEDURE
Intervention: Home Care/RAI-HC Assessment
Description: Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
Study NCT01776281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Study NCT01776281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study NCT00645489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
Study NCT00645489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: wait list
Description: Wait list